{
  "question": "Patient Clinical Profile:\nAge: 50 years old,Sex: M,Height: 167.5 cm,Body weight: 73.4 kg,BMI: 26.16,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 60%,WBC: 6.89,Albumin: 4.4 g/dL,Lymphocyte: 2.55,Neutrophil: 3.46,LDH level: 176.0 U/L,Treatment type: Immunotherapy,Treatment regimen: AMG404,SNV mutations: CDKN2A,CTCF,CNV alterations: ATM(gain),BRAF(gain),CCND3(gain),CDK6(gain),CHEK1(gain),EGFR(gain),MET(gain),MYCL(gain),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?",
  "options": {
    "A": "Complete Response",
    "B": "Partial Response",
    "C": "Stable Disease",
    "D": "Progressive Disease"
  },
  "answer_idx": "B",
  "answer": "PR",
  "process_id": 83,
  "options_str": "A. Complete Response\nB. Partial Response\nC. Stable Disease\nD. Progressive Disease",
  "gpt_filter_query": "<Multiple-choice Question>\nPatient Clinical Profile:\nAge: 50 years old,Sex: M,Height: 167.5 cm,Body weight: 73.4 kg,BMI: 26.16,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 60%,WBC: 6.89,Albumin: 4.4 g/dL,Lymphocyte: 2.55,Neutrophil: 3.46,LDH level: 176.0 U/L,Treatment type: Immunotherapy,Treatment regimen: AMG404,SNV mutations: CDKN2A,CTCF,CNV alterations: ATM(gain),BRAF(gain),CCND3(gain),CDK6(gain),CHEK1(gain),EGFR(gain),MET(gain),MYCL(gain),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?\nA. Complete Response\nB. Partial Response\nC. Stable Disease\nD. Progressive Disease\nCorrect Answer: PR\n</Multiple-choice Question>\n\nYou are an expert in filtering and evaluating multiple-choice questions for advanced reasoning tasks. Your job is to evaluate a given question and determine whether it meets the following criteria: \n1. **Depth of Reasoning:** The question should require deeper reasoning. If the question appears too simple, mark it as \"Too Simple\".\n2. **Unambiguous Correct Answer:** The question must have a unique and unambiguous correct answer. If the question asks for \"incorrect options\" or allows for multiple correct answers, mark it as \"Ambiguous Answer\".\n3. **Open-Ended Reformulation Feasibility:** The question should be suitable for reformatting into an open-ended format. If the question cannot be easily reformulated into an open-ended problem and a clear ground-truth answer, mark it as \"Not Reformulatable\".\n\nFor each question, provide one of the following evaluations:  \n- \"Pass\" (The question meets all the criteria.)  \n- \"Too Simple\"  \n- \"Ambiguous Answer\"  \n- \"Not Reformulatable\" ",
  "gpt_filter_response": "\"Pass\"",
  "gpt_reformat_query": "I will provide you with a multiple-choice question, and your task is to rewrite it into an open-ended question, along with a Ground-True Answer. The requirements are:\n\n1. The question must be specific, targeting the point being tested in the original multiple-choice question. Ensure it is open-ended, meaning no options are provided, but there must be a definitive Ground-True Answer.\n2. Based on the correct answer from the original question, provide a concise Ground-True Answer. The answer should allow for precise matching to determine whether the model's response is correct.\n\nHere is the multiple-choice question for you to rewrite:\n<Multiple-choice Question>\nPatient Clinical Profile:\nAge: 50 years old,Sex: M,Height: 167.5 cm,Body weight: 73.4 kg,BMI: 26.16,Smoking history: Current smoker,Cancer stage: Non SqCC,Histology: adenocarcinoma,Liver metastasis: No,Brain metastasis: Yes,EGFR status: Wild,ALK status: Negative,ROS1 status: Negative,PD-L1 group: >50%,PD-L1 (SP263): 60%,WBC: 6.89,Albumin: 4.4 g/dL,Lymphocyte: 2.55,Neutrophil: 3.46,LDH level: 176.0 U/L,Treatment type: Immunotherapy,Treatment regimen: AMG404,SNV mutations: CDKN2A,CTCF,CNV alterations: ATM(gain),BRAF(gain),CCND3(gain),CDK6(gain),CHEK1(gain),EGFR(gain),MET(gain),MYCL(gain),Fusion genes: None,Splice variants: None,TMB: 7.9 mutations/Mb\nWhat is the most likely treatment response?\nA. Complete Response\nB. Partial Response\nC. Stable Disease\nD. Progressive Disease\nCorrect Answer: PR\n</Multiple-choice Question>\n\nPlease output the result in the following JSON format:\n```json\n{\n\"Open-ended Verifiable Question\": \"...\",\n\"Ground-True Answer\": \"...\"\n}\n```",
  "gpt_reformat_response": "```json\n{\n  \"Open-ended Verifiable Question\": \"Based on a 50-year-old male patient with non-SqCC adenocarcinoma showing PD-L1 expression of 60%, brain metastasis, EGFR wild type, ALK and ROS1 negative status, who is a current smoker and receiving immunotherapy with AMG404, what is the most likely treatment response?\",\n  \"Ground-True Answer\": \"Partial Response\"\n}\n```",
  "Open-ended Verifiable Question": "Based on a 50-year-old male patient with non-SqCC adenocarcinoma showing PD-L1 expression of 60%, brain metastasis, EGFR wild type, ALK and ROS1 negative status, who is a current smoker and receiving immunotherapy with AMG404, what is the most likely treatment response?",
  "Ground-True Answer": "Partial Response",
  "verify": [
    true
  ],
  "Long_CoT": [
    {
      "action": "Inner Thinking",
      "title": "Understanding the Role of PD-L1 Expression",
      "content": "In non-small cell lung cancer (NSCLC), particularly non-squa-mous adenocarcinoma, PD-L1 expression is a critical factor in considering immunotherapy options. A PD-L1 expression of 60% is considered high, which generally predicts a better response to PD-1 or PD-L1 inhibitors such as AMG404, which is a PD-1 inhibitor."
    },
    {
      "action": "Inner Thinking",
      "title": "Impact of Smoking on Treatment",
      "content": "Smoking history, such as in this case where the patient is a current smoker, can affect tumor mutation burden (TMB). Higher TMB is often associated with a better response to immunotherapy. As a result, smokers may exhibit better responses to immunotherapy compared to non-smokers due to higher TMB."
    },
    {
      "action": "Inner Thinking",
      "title": "Consideration of Brain Metastasis",
      "content": "The presence of brain metastasis is often a poor prognostic factor in NSCLC. However, certain PD-1 inhibitors have shown activity in controlling brain metastases. Thus, AMG404 may still provide benefit if it crosses the blood-brain barrier or induces systemic immune response that affects the brain lesions."
    },
    {
      "action": "Inner Thinking",
      "title": "Genomic Profile and Its Impact",
      "content": "The genomic profile indicating EGFR wild type, ALK and ROS1 negative rules out targeted therapies for these mutations. This makes immunotherapy the most suitable option based on the PD-L1 expression level. The lack of these mutations means there are no additional targets for distinct therapies, reinforcing immunotherapy as the primary strategy."
    },
    {
      "action": "Final Conclusion",
      "content": "Given the patient's high PD-L1 expression, smoking history, and lack of targetable mutations, the most likely treatment response to AMG404 in this patient is a positive response to immunotherapy, including potential partial response or stable disease."
    },
    {
      "action": "Verification",
      "content": "The conclusion aligns with current understanding of oncological therapies. High PD-L1 expression, especially above 50%, generally predicts a favorable response to PD-1 inhibitors. The positive impact of smoking on TMB further supports this response. With cerebral lesions, systemic activity of immunotherapy could lead to control in CNS as well. Therefore, the final conclusion is verified to be consistent with clinical evidence."
    }
  ],
  "gpt4_query_cot": [
    "<question>\nBased on a 50-year-old male patient with non-SqCC adenocarcinoma showing PD-L1 expression of 60%, brain metastasis, EGFR wild type, ALK and ROS1 negative status, who is a current smoker and receiving immunotherapy with AMG404, what is the most likely treatment response?\n</question>\n\nPlease respond to the above question <question> using the Chain of Thought (CoT) reasoning method. Your response should consist of multiple steps, each of which includes three types of actions: **\"Inner Thinking\"**, **\"Final Conclusion\"**, and **\"Verification\"**:\n\n- **'Inner Thinking'**: This is the step where thinking is done. Note that multiple 'Inner Thinking' steps are required to describe thorough reasoning. Each step should first generate a brief title.\n- **'Final Conclusion'**: At this stage, you summarize the correct reasoning from previous 'Inner Thinking' steps and provide the final answer. No title is required here.\n- **'Verification'**: At this stage, you verify the conclusion from the \"Final Conclusion\" step. If the conclusion holds, end the process. If not, return to \"Inner Thinking\" for further reasoning. No title is required here.\n\nThe output format must strictly follow the JSON structure below:\n```json\n{\n\"CoT\": [\n    {\"action\": \"Inner Thinking\", \"title\": \"...\", \"content\": \"...\"},\n    ...,\n    {\"action\": \"Final Conclusion\", \"content\": \"...\"},\n    {\"action\": \"Verification\", \"content\": \"...\"}\n]\n}\n```",
    "<Model Response>  \nGiven the patient's high PD-L1 expression, smoking history, and lack of targetable mutations, the most likely treatment response to AMG404 in this patient is a positive response to immunotherapy, including potential partial response or stable disease.  \n</Model Response>  \n\n<Reference Answer>  \nPartial Response\n</Reference Answer>  \n\nYou are provided with a model-generated response (<Model Response>) and a reference answer (<Reference Answer>). Compare the model response with the reference answer and determine its correctness. Your task is to simply output \"True\" if the response is correct, and \"False\" otherwise.",
    "<Thought Process>\n### Understanding the Role of PD-L1 Expression\nIn non-small cell lung cancer (NSCLC), particularly non-squa-mous adenocarcinoma, PD-L1 expression is a critical factor in considering immunotherapy options. A PD-L1 expression of 60% is considered high, which generally predicts a better response to PD-1 or PD-L1 inhibitors such as AMG404, which is a PD-1 inhibitor.\n\n### Impact of Smoking on Treatment\nSmoking history, such as in this case where the patient is a current smoker, can affect tumor mutation burden (TMB). Higher TMB is often associated with a better response to immunotherapy. As a result, smokers may exhibit better responses to immunotherapy compared to non-smokers due to higher TMB.\n\n### Consideration of Brain Metastasis\nThe presence of brain metastasis is often a poor prognostic factor in NSCLC. However, certain PD-1 inhibitors have shown activity in controlling brain metastases. Thus, AMG404 may still provide benefit if it crosses the blood-brain barrier or induces systemic immune response that affects the brain lesions.\n\n### Genomic Profile and Its Impact\nThe genomic profile indicating EGFR wild type, ALK and ROS1 negative rules out targeted therapies for these mutations. This makes immunotherapy the most suitable option based on the PD-L1 expression level. The lack of these mutations means there are no additional targets for distinct therapies, reinforcing immunotherapy as the primary strategy.\n\n### Conclusion\nGiven the patient's high PD-L1 expression, smoking history, and lack of targetable mutations, the most likely treatment response to AMG404 in this patient is a positive response to immunotherapy, including potential partial response or stable disease.\n\n### Verification\nThe conclusion aligns with current understanding of oncological therapies. High PD-L1 expression, especially above 50%, generally predicts a favorable response to PD-1 inhibitors. The positive impact of smoking on TMB further supports this response. With cerebral lesions, systemic activity of immunotherapy could lead to control in CNS as well. Therefore, the final conclusion is verified to be consistent with clinical evidence.\n</Thought Process>\n\n<Question>\nBased on a 50-year-old male patient with non-SqCC adenocarcinoma showing PD-L1 expression of 60%, brain metastasis, EGFR wild type, ALK and ROS1 negative status, who is a current smoker and receiving immunotherapy with AMG404, what is the most likely treatment response?\n</Question>\n\nThe <Thought Process> above reflects the model's reasoning based on the <Question>. Your task is to rewrite the <Thought Process> to resemble a more human-like, intuitive natural thinking process. The new version should:\n\n1. Be presented as step-by-step reasoning, with each thought on a new line separated by a line break.\n2. Avoid structured titles or formatting, focusing on natural transitions. Use casual and natural language for transitions or validations, such as \"hmm,\" \"oh,\" \"also,\" or \"wait.\"\n3. Expand the content, making the reasoning richer, more detailed, and logically clear while still being conversational and intuitive.\n\nReturn directly the revised natural thinking in JSON format as follows:\n```json\n{\n  \"NaturalReasoning\": \"...\"\n}\n```",
    "<Internal Thinking>\nAlright, so we have a 50-year-old male with non-small cell lung cancer, specifically the adenocarcinoma type, right? And his PD-L1 expression is at 60%. That's pretty high. From what I know, high PD-L1 means he's more likely to respond well to PD-1 or PD-L1 inhibitors. AMG404, that PD-1 inhibitor, should be a good fit for him.\n\nNow, let's consider his smoking history. He's a current smoker. Smoking can lead to higher tumor mutation burden, which is often linked to better responses to immunotherapy. It seems like being a smoker might actually work in his favor here, which is ironic.\n\nThen there's the fact that he has brain metastasis. That's typically not a good sign because it can make treatment more complicated. But there's a silver lining: some PD-1 inhibitors have been effective in dealing with brain metastases. I hope AMG404 can cross the blood-brain barrier or at least trigger a systemic immune response that can reach his brain.\n\nLet's look at his genomic profile: EGFR wild type, and negative for ALK and ROS1. This basically narrows down his treatment options because targeted therapies aren't available for him. So, it seems like immunotherapy, especially given his high PD-L1 expression, is really his best shot.\n\nPutting all of this together, I'm thinking he should respond positively to AMG404. He could see a partial response or, at least, stable disease. With all these factors, the treatment has a good shot at being effective.\n\nEverything seems to add up. High PD-L1 typically means better response to PD-1 inhibitors, his smoking history likely increases his TMB in a favorable way, and while brain metastasis adds complexity, the systemic effect of immunotherapy offers hope. Yeah, it looks like a consistent and logical conclusion given what we know.\n</Internal Thinking>\n\n<Question>\nBased on a 50-year-old male patient with non-SqCC adenocarcinoma showing PD-L1 expression of 60%, brain metastasis, EGFR wild type, ALK and ROS1 negative status, who is a current smoker and receiving immunotherapy with AMG404, what is the most likely treatment response?\n</Question>\n\nThe <Internal Thinking> represents your internal thoughts about the <Question>. Based on this, generate a rich and high-quality final response to the user. If there is a clear answer, provide it first. Ensure your final response closely follows the <Question>. The response style should resemble GPT-4's style as much as possible. Output only your final response, without any additional content."
  ],
  "gpt4_response_cot": [
    "```json\n{\n    \"CoT\": [\n        {\"action\": \"Inner Thinking\", \"title\": \"Understanding the Role of PD-L1 Expression\", \"content\": \"In non-small cell lung cancer (NSCLC), particularly non-squa-mous adenocarcinoma, PD-L1 expression is a critical factor in considering immunotherapy options. A PD-L1 expression of 60% is considered high, which generally predicts a better response to PD-1 or PD-L1 inhibitors such as AMG404, which is a PD-1 inhibitor.\"},\n        {\"action\": \"Inner Thinking\", \"title\": \"Impact of Smoking on Treatment\", \"content\": \"Smoking history, such as in this case where the patient is a current smoker, can affect tumor mutation burden (TMB). Higher TMB is often associated with a better response to immunotherapy. As a result, smokers may exhibit better responses to immunotherapy compared to non-smokers due to higher TMB.\"},\n        {\"action\": \"Inner Thinking\", \"title\": \"Consideration of Brain Metastasis\", \"content\": \"The presence of brain metastasis is often a poor prognostic factor in NSCLC. However, certain PD-1 inhibitors have shown activity in controlling brain metastases. Thus, AMG404 may still provide benefit if it crosses the blood-brain barrier or induces systemic immune response that affects the brain lesions.\"},\n        {\"action\": \"Inner Thinking\", \"title\": \"Genomic Profile and Its Impact\", \"content\": \"The genomic profile indicating EGFR wild type, ALK and ROS1 negative rules out targeted therapies for these mutations. This makes immunotherapy the most suitable option based on the PD-L1 expression level. The lack of these mutations means there are no additional targets for distinct therapies, reinforcing immunotherapy as the primary strategy.\"},\n        {\"action\": \"Final Conclusion\", \"content\": \"Given the patient's high PD-L1 expression, smoking history, and lack of targetable mutations, the most likely treatment response to AMG404 in this patient is a positive response to immunotherapy, including potential partial response or stable disease.\"},\n        {\"action\": \"Verification\", \"content\": \"The conclusion aligns with current understanding of oncological therapies. High PD-L1 expression, especially above 50%, generally predicts a favorable response to PD-1 inhibitors. The positive impact of smoking on TMB further supports this response. With cerebral lesions, systemic activity of immunotherapy could lead to control in CNS as well. Therefore, the final conclusion is verified to be consistent with clinical evidence.\"}\n    ]\n}\n```",
    "True",
    "```json\n{\n  \"NaturalReasoning\": \"Alright, so we have a 50-year-old male with non-small cell lung cancer, specifically the adenocarcinoma type, right? And his PD-L1 expression is at 60%. That's pretty high. From what I know, high PD-L1 means he's more likely to respond well to PD-1 or PD-L1 inhibitors. AMG404, that PD-1 inhibitor, should be a good fit for him.\\n\\nNow, let's consider his smoking history. He's a current smoker. Smoking can lead to higher tumor mutation burden, which is often linked to better responses to immunotherapy. It seems like being a smoker might actually work in his favor here, which is ironic.\\n\\nThen there's the fact that he has brain metastasis. That's typically not a good sign because it can make treatment more complicated. But there's a silver lining: some PD-1 inhibitors have been effective in dealing with brain metastases. I hope AMG404 can cross the blood-brain barrier or at least trigger a systemic immune response that can reach his brain.\\n\\nLet's look at his genomic profile: EGFR wild type, and negative for ALK and ROS1. This basically narrows down his treatment options because targeted therapies aren't available for him. So, it seems like immunotherapy, especially given his high PD-L1 expression, is really his best shot.\\n\\nPutting all of this together, I'm thinking he should respond positively to AMG404. He could see a partial response or, at least, stable disease. With all these factors, the treatment has a good shot at being effective.\\n\\nEverything seems to add up. High PD-L1 typically means better response to PD-1 inhibitors, his smoking history likely increases his TMB in a favorable way, and while brain metastasis adds complexity, the systemic effect of immunotherapy offers hope. Yeah, it looks like a consistent and logical conclusion given what we know.\"\n}\n```",
    "Based on the details provided, the patient is likely to have a favorable response to the immunotherapy with AMG404, a PD-1 inhibitor. Given the high PD-L1 expression level of 60%, there's an increased likelihood of a positive response to PD-1 inhibitors like AMG404. The fact that the patient is a current smoker might contribute to a higher tumor mutation burden, which is often correlated with a better response to immunotherapy.\n\nWhile the presence of brain metastasis traditionally complicates treatment, some PD-1 inhibitors have demonstrated effectiveness in patients with brain metastases either by directly acting on tumor cells in the brain or by inducing a systemic immune response. Furthermore, the absence of actionable mutations (EGFR wild type, ALK, and ROS1 negative) limits the use of targeted therapies, making immunotherapy a suitable option.\n\nGiven these factors, the patient could experience a partial response or stable disease with AMG404, indicating that the treatment is potentially effective in managing his condition."
  ],
  "response_struct": [
    [
      {
        "action": "Inner Thinking",
        "title": "Understanding the Role of PD-L1 Expression",
        "content": "In non-small cell lung cancer (NSCLC), particularly non-squa-mous adenocarcinoma, PD-L1 expression is a critical factor in considering immunotherapy options. A PD-L1 expression of 60% is considered high, which generally predicts a better response to PD-1 or PD-L1 inhibitors such as AMG404, which is a PD-1 inhibitor."
      },
      {
        "action": "Inner Thinking",
        "title": "Impact of Smoking on Treatment",
        "content": "Smoking history, such as in this case where the patient is a current smoker, can affect tumor mutation burden (TMB). Higher TMB is often associated with a better response to immunotherapy. As a result, smokers may exhibit better responses to immunotherapy compared to non-smokers due to higher TMB."
      },
      {
        "action": "Inner Thinking",
        "title": "Consideration of Brain Metastasis",
        "content": "The presence of brain metastasis is often a poor prognostic factor in NSCLC. However, certain PD-1 inhibitors have shown activity in controlling brain metastases. Thus, AMG404 may still provide benefit if it crosses the blood-brain barrier or induces systemic immune response that affects the brain lesions."
      },
      {
        "action": "Inner Thinking",
        "title": "Genomic Profile and Its Impact",
        "content": "The genomic profile indicating EGFR wild type, ALK and ROS1 negative rules out targeted therapies for these mutations. This makes immunotherapy the most suitable option based on the PD-L1 expression level. The lack of these mutations means there are no additional targets for distinct therapies, reinforcing immunotherapy as the primary strategy."
      },
      {
        "action": "Final Conclusion",
        "content": "Given the patient's high PD-L1 expression, smoking history, and lack of targetable mutations, the most likely treatment response to AMG404 in this patient is a positive response to immunotherapy, including potential partial response or stable disease."
      },
      {
        "action": "Verification",
        "content": "The conclusion aligns with current understanding of oncological therapies. High PD-L1 expression, especially above 50%, generally predicts a favorable response to PD-1 inhibitors. The positive impact of smoking on TMB further supports this response. With cerebral lesions, systemic activity of immunotherapy could lead to control in CNS as well. Therefore, the final conclusion is verified to be consistent with clinical evidence."
      }
    ]
  ],
  "response_type": [
    "Init_CoT"
  ],
  "prior_fail_try": [],
  "Complex_CoT": "Alright, so we have a 50-year-old male with non-small cell lung cancer, specifically the adenocarcinoma type, right? And his PD-L1 expression is at 60%. That's pretty high. From what I know, high PD-L1 means he's more likely to respond well to PD-1 or PD-L1 inhibitors. AMG404, that PD-1 inhibitor, should be a good fit for him.\n\nNow, let's consider his smoking history. He's a current smoker. Smoking can lead to higher tumor mutation burden, which is often linked to better responses to immunotherapy. It seems like being a smoker might actually work in his favor here, which is ironic.\n\nThen there's the fact that he has brain metastasis. That's typically not a good sign because it can make treatment more complicated. But there's a silver lining: some PD-1 inhibitors have been effective in dealing with brain metastases. I hope AMG404 can cross the blood-brain barrier or at least trigger a systemic immune response that can reach his brain.\n\nLet's look at his genomic profile: EGFR wild type, and negative for ALK and ROS1. This basically narrows down his treatment options because targeted therapies aren't available for him. So, it seems like immunotherapy, especially given his high PD-L1 expression, is really his best shot.\n\nPutting all of this together, I'm thinking he should respond positively to AMG404. He could see a partial response or, at least, stable disease. With all these factors, the treatment has a good shot at being effective.\n\nEverything seems to add up. High PD-L1 typically means better response to PD-1 inhibitors, his smoking history likely increases his TMB in a favorable way, and while brain metastasis adds complexity, the systemic effect of immunotherapy offers hope. Yeah, it looks like a consistent and logical conclusion given what we know.",
  "Response": "Based on the details provided, the patient is likely to have a favorable response to the immunotherapy with AMG404, a PD-1 inhibitor. Given the high PD-L1 expression level of 60%, there's an increased likelihood of a positive response to PD-1 inhibitors like AMG404. The fact that the patient is a current smoker might contribute to a higher tumor mutation burden, which is often correlated with a better response to immunotherapy.\n\nWhile the presence of brain metastasis traditionally complicates treatment, some PD-1 inhibitors have demonstrated effectiveness in patients with brain metastases either by directly acting on tumor cells in the brain or by inducing a systemic immune response. Furthermore, the absence of actionable mutations (EGFR wild type, ALK, and ROS1 negative) limits the use of targeted therapies, making immunotherapy a suitable option.\n\nGiven these factors, the patient could experience a partial response or stable disease with AMG404, indicating that the treatment is potentially effective in managing his condition.",
  "Question": "Based on a 50-year-old male patient with non-SqCC adenocarcinoma showing PD-L1 expression of 60%, brain metastasis, EGFR wild type, ALK and ROS1 negative status, who is a current smoker and receiving immunotherapy with AMG404, what is the most likely treatment response?"
}